Back


12/10/2017
Zealand has initiated a clinical trial to evaluate the potential for less than once-daily dosing with its long-acting GLP-2 analog glepaglutide
Zealand Pharma announces dosing has started in a clinical trial with glepaglutide under an investigational new drug application (IND) for the treatment of short bowel syndrome (SBS). Glepaglutide is a novel long-acting GLP-2 analog under development for the treatment of SBS. [...]

Download the pdf file





X

X